URCC NCORP Research Base
Funded at University of Rochester · NIH-11543567 · Data updated 2026-11-12
A cancer care research program helps community clinics improve how they support people with cancer and reduce treatment-related side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 1, 2014 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $5,980,962 |
| NIH project number | 4UG1CA189961-12 |
| Project ID | NIH-11543567 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancer treated in community oncology settings, along with survivors and caregivers, who may participate in trials or implementation projects.
✕Less likely to help
Some participants may not experience immediate personal benefit if their specific condition or treatment plan is not addressed by the local studies.
What this research studies
This grant supports the URCC NCORP Research Base, which partners with community oncology sites to conduct cancer control and care delivery research. It focuses on reducing morbidity from cancer and its treatments and on improving the patient and caregiver experience in real-world settings. Researchers engage community clinics, enroll patients and survivors, and train clinicians to implement proven approaches across multiple sites. The work highlights collaboration with community partners to advance practical, patient-centered cancer care.
Why it matters
Potential benefit: If successful, the program could lead to better symptom management, fewer toxicities, and improved quality of life for people living with cancer and their caregivers.
How similar studies have gone: Past URCC NCORP work has produced numerous publications, presentations, and trained personnel, indicating a track record of meaningful, practice-oriented findings.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Mustian, Karen M. — University of Rochester
- Study coordinator: Mustian, Karen M.
Related research
Other NIH-funded projects on the same topics.
-
Rapid automated breast lump diagnosis without a radiologist or sonographer
A new AI-powered ultrasound tool helps determine if a palpable breast lump is likely benign or malignant, using a simplified technique that can be used by people with minimal ultrasound training.
-
ML-ROVER: Reducing Unneeded Lab Tests in Kids with AI
Aims to use machine learning to cut unnecessary blood tests in children in intensive care, helping avoid anemia and improve care quality.
-
Aggressive fever-reducing therapy to protect the brains of children with CNS malaria
A study planned for children with CNS malaria will test whether aggressive fever-reducing treatment can lower death and brain-related problems.
-
Aggressive fever-reducing therapy to protect brains in children with CNS malaria
A plan to test whether giving strong fever-reducing medications to children with central nervous system malaria can lower death and brain injury.
-
Aggressive fever-fighting treatment to protect the brain in kids with CNS malaria
A plan to test whether giving strong fever-reducing treatment alongside standard care can lower death and brain injury in children with CNS malaria.
-
Aggressive fever-reducing treatment to protect brains in kids with CNS malaria
A plan to test whether giving strong fever-reducing medicine alongside standard malaria treatment can lower deaths and brain injuries in children with CNS malaria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.